Astrotech Corporation (NASDAQ: ASTC) — Form 10-Q Summary
Period clarification: The request identifies “2021 Q2,” but the supplied filing is for the quarter ended December 31, 2022 (Astrotech fiscal 2023 second quarter), filed February 13, 2023. Financial amounts below are in thousands of dollars unless stated otherwise.
Business context and reporting period
Astrotech commercializes mass spectrometry technology through its wholly owned subsidiaries: 1st Detect (security and explosives trace detection), AgLAB (hemp and cannabis processing), and BreathTech (breath-based disease screening). The filing reports the three and six months ended December 31, 2022, compared with the same periods in 2021.
Key financial metrics
| Metric | Three months ended Dec. 31, 2022 | Three months ended Dec. 31, 2021 | Six months ended Dec. 31, 2022 | Six months ended Dec. 31, 2021 |
|---|---|---|---|---|
| Revenue | $263 | $561 | $301 | $748 |
| Gross profit / margin | $108 / 41% | $120 / 21% | $114 / 38% | $132 / 18% |
| Operating expenses | $2,922 | $2,380 | $5,692 | $4,445 |
| Operating loss | $(2,814) | $(2,260) | $(5,578) | $(4,313) |
| Net loss | $(2,418) | $(2,180) | $(4,947) | $(4,209) |
| Net loss per share | $(1.50) | $(1.38) | $(3.07) | $(2.66) |
| Operating cash used | Not separately reported | Not separately reported | $(4,255) | $(3,484) |
At December 31, 2022, cash and cash equivalents were $15.9 million and short-term investments were $31.0 million, for combined cash and short-term investments of approximately $46.8 million. Working capital was approximately $47.2 million. Total liabilities were $2.6 million, including $647,000 of lease liabilities; the $500,000 related-party note was repaid in September 2022. The company reported no material off-balance-sheet arrangements.
Material changes versus the prior comparable period
- Quarterly revenue fell 53% to $263,000; six-month revenue fell 60% to $301,000. Management attributed the declines primarily to shifting sales focus away from the volatile explosives trace detection market toward AgLAB. Revenue remained principally tied to TRACER 1000 products, rentals, consumables, and maintenance.
- Gross margin improved to 41% for the quarter and 38% for the six-month period, versus 21% and 18%, respectively, attributed to a higher share of recurring revenue.
- Quarterly R&D expense rose $712,000 (109%) and six-month R&D expense rose $1.2 million (93%), reflecting technology improvements, AgLAB development and trials, additional headcount and BreathTech research support. Operating losses increased in both comparison periods.
- Other income increased, supported by interest earned on investments as rates rose. For the six-month period, the comparison also reflects reduced interest expense after repayment of related-party debt.
- Cash and cash equivalents declined $10.6 million from June 30, 2022, partly because the company purchased short-term investments. The cash flow statement reports $5.1 million of security purchases and $632,000 of property and equipment purchases during the six months.
Outlook, risks, contingencies, and unusual items
- No quantified revenue, earnings, or cash-flow guidance is provided. Management says AgLAB may offer a more profitable opportunity than the commoditized ETD market; AgLAB production and sales efforts had begun, but commercial results are not assured.
- TRACER 1000 had been deployed at approximately 21 locations in 14 countries. TSA cargo detection testing remained ongoing and slower than anticipated; final approval is needed for U.S. air-cargo sales.
- BreathTech expanded its Cleveland Clinic research project to additional diseases. The filing describes preliminary ability to distinguish background breath from disease VOCs, not validated commercial performance.
- Management cites semiconductor and electronics shortages, product-cost inflation, and uncertain recovery in air travel. It is seeking alternative suppliers and expects to pass some cost increases to customers, but prolonged shortages could hurt results.
- A $1.0 million share repurchase authorization runs through November 17, 2023; no shares were repurchased in the quarter. The company completed a 1-for-30 reverse split and regained Nasdaq’s minimum-bid-price compliance in December 2022.
- A Delaware stockholder class and derivative action remains pending settlement approval. The court had validated the challenged charter amendment, and the company was awaiting a court decision on the settlement.
- The company recorded no income-tax benefit and maintained a full valuation allowance on deferred tax assets. It disclosed approximately $400,000 of uncertain tax positions and does not expect significant changes in the next 12 months.
Most important facts for investors to verify
- Confirm the intended reporting period: the supplied filing is fiscal Q2 2023, not 2021 Q2.
- Track whether AgLAB sales grow enough to offset declining TRACER-related revenue and whether margins remain improved.
- Check progress and timing of final TSA cargo testing and any resulting U.S. approvals or orders.
- Monitor operating cash burn and liquidity, including the mix, maturities, and market value of short-term investments.
- Review the outcome of the pending Delaware settlement and any material supply-chain or customer-concentration developments.